基因編輯：Lonza 4D-NucleofectorTM技術(shù)可以將Crispr-Cas9、質(zhì)粒等基因編輯工具有效傳遞到免疫細(xì)胞 (特異性免疫細(xì)胞、非特異性免疫細(xì)胞抗原提呈細(xì)胞等)中，從而精確修改細(xì)胞的遺傳物質(zhì)，例如敲入或敲除特定基因�；�因編輯可以增強(qiáng)免疫細(xì)胞識(shí)別、靶向癌細(xì)胞或調(diào)節(jié)其對(duì)自身免疫性疾病反應(yīng)的能力。

CAR-T/CAR-NK等細(xì)胞療法：電穿孔在嵌合抗原受體(CAR)T/NK等細(xì)胞療法的發(fā)展中發(fā)揮著至關(guān)重要的作用。通過(guò)使用LonzaNucleofectorTM技術(shù)，研究人員可以將CAR結(jié)構(gòu)引入T/NK等細(xì)胞，以表達(dá)特異性識(shí)別癌細(xì)胞的受體，從而使得CAR-T/CAR-NK等細(xì)胞能夠更有效地靶向并殺死癌細(xì)胞。也可以將T/NK等細(xì)胞的特異性免疫位點(diǎn)進(jìn)行敲除、改造，從而獲得通用型CAR-T/CAR-NK等。

抗原呈遞：樹(shù)突狀細(xì)胞(DC)通過(guò)向T細(xì)胞呈遞抗原來(lái)啟動(dòng)免疫反應(yīng)。Lonza 4D-NucleofectorTM技術(shù)可用于將抗原或編碼抗原的核酸遞送至樹(shù)突狀細(xì)胞，從而增強(qiáng)抗原呈遞，并激活針對(duì)病原體或癌細(xì)胞的特異性免疫反應(yīng)。

疫苗開(kāi)發(fā)：通過(guò)使用Lonza4D-NucleofectorTM技術(shù)，可將編碼抗原的的質(zhì)粒DNA直接遞送到免疫細(xì)胞中，刺激強(qiáng)大的免疫反應(yīng)，從而產(chǎn)生特異性抗體和T細(xì)胞反應(yīng)。

免疫治療研究：電穿孔是研究免疫細(xì)胞生物學(xué)和功能的重要工具。通過(guò)使用Lonza4DNucleofectorTM 技術(shù)，可將各種分子(包括siRNA、miRNA、細(xì)胞因子和信號(hào)分子等)遞送到免疫細(xì)胞中，以研究它們對(duì)免疫反應(yīng)和治療潛力的影響。

相關(guān)文獻(xiàn)

Roth, T.L., Puig-Saus, C., Yu, R.et al.

Reprogramming human T cell function andspecificity with non-viral genome targeting. Nature559,405-409(2018)

https://doiorg/10.1038/s41586-018-0326-5

Akiko Seki,Sascha Rutz: Optimized RNPtransfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.J ExpMed 5 March 2018:215(3):985-997.https://doiorg/10.1084/jem.20171626

Emily C.Freund,Jaclyn Y. Lock,Jaehak Oh,TimursMaculins,Lelia Delamarre, Christopher J. Bohlen

Benjamin Haley,Aditya Murthy; Efficient gene

knockoutin primary human and murine mveloid

cells by non-viral delivery of CRISPR-Cas9.J ExpMed 6 July 2020:217 (7): e20191692.

https://doi.org/10.1084/jem.20191692

Ma,S., Sun,B., Duan, S.et al. YTHDF2 orchestratestumor-associated macrophage reprogramming andcontrols antitumorimmunity through CD8+ T cells.NatImmunol24255-266(2023)

https://doiorg/10.1038/s41590-022-01398-6

Chen.YP..Yin.JH.. Li,WF.et al.Single-celltranscriptomics reveals regulators underlyingimmune cell diversity and immune subtypesassociated with prognosis in nasopharyngealcarcinoma.Cell Res 301024-1042(2020)

https://doiorg/10.1038/s41422-020-0374-x

Chakraborty. Krishnendu,et al."A Novel CRISPREngineered,Stem Cell-Derived Cellular Vaccine.bioRxiv(2021):2021-12.

https://doiorg/10.1101/20211228474336